DSIP vial

As research shows

DSIP is a nonapeptide (~849 Da) reported to cross the blood–brain and blood–CSF barriers in animal models and has been explored in human sleep studies.

• Neurophysiology: Modulation of EEG patterns linked to slow‑wave (delta) sleep has been observed in several studies and reviews.
• Hormonal/Stress Axes: Investigations have explored effects on ACTH/cortisol dynamics and interactions with other neuroendocrine pathways.
• Routes Studied: Intravenous (slow infusion), intranasal, and (in animals) subcutaneous; human literature most often used IV.

Key benefits

Clinical findings vary across trials; reported improvements in sleep parameters (e.g., total sleep time, awakenings)

>>Reported outcomes include changes in total sleep time, sleep latency, awakenings, and sleep efficiency

>>Open‑label and small controlled studies suggest possible short‑term benefits; effects may be modest and inconsistent

>>Short‑term studies reported few adverse effects; rigorous long‑term safety data are limited